Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/add.16476 | DOI Listing |
J Stud Alcohol Drugs
October 2024
University at Buffalo, State University of New York.
The rescheduling of cannabis, from the US Drug Enforcement Administration (DEA), current most restrictive (Schedule 1) designation, would be an important step for cannabis research and researchers. We are researchers who have experience with cannabis research in pre-clinical, clinical, and policy domains, who represent a range of social science disciplines (e.g.
View Article and Find Full Text PDFAddiction
June 2024
Center for Interdisciplinary Addiction Research (ZIS), Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Intern Med J
December 2023
Department of Gastroenterology & Hepatology, Flinders Medical Centre, Adelaide, South Australia, Australia.
Background: Codeine-containing compound analgesics (CCCAs) are associated with dependence and, when taken in excess, significant risks of harm. A previous audit showed significant costs related to admissions for gastrointestinal (GI) complications of CCCA. Based on this and other evidence of harm, the Australian Therapeutic Goods Administration changed CCCAs to prescription only in 2018.
View Article and Find Full Text PDFJDR Clin Trans Res
October 2023
Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.
Introduction: In the United States, dentists frequently prescribe hydrocodone. In October 2014, the US Drug Enforcement Administration rescheduled hydrocodone from controlled substance schedule III to II, introducing more restricted prescribing and dispensing regulations, which may have changed dental prescribing of opioids.
Objective: The study aim was to evaluate the impact of the hydrocodone rescheduling on dental prescribing of opioids in the United States.
Addiction
March 2022
University of Tasmania, Hobart, TAS, Australia.
Aim: To evaluate and document the impacts of re-scheduling codeine to a prescription-only medication in Australia in February 2018.
Design: Prospective cohort study. Participants completed an on-line survey with a range of outcome measures at four time-points, once before codeine was re-scheduled (November 2017) and three times after the event: 1 month after (February 2018), 4 months after (June 2018) and 12 months after (February 2019).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!